April 18th 2024
Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Tafasitamab Plus Lenalidomide Improve Outcomes Vs Systemic Therapies in Relapsed/Refractory DLBCL
October 9th 2022Tafasitamab plus lenalidomide prolonged overall survival compared with systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma, according to data from the retrospective RE-MIND2 study.
Tazemetostat in R/R FL: Original Trial Data and a Propensity Score-Matched Analysis
September 29th 2022Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.
Kami J. Maddocks, MD, Provides Insight Into the Biggest Breakthroughs in Lymphoma Thus Far in 2022
September 1st 2022Kami J. Maddocks, MD, talks CAR T-cell therapy approvals for the treatment of relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma plus a new treatment supplanting R-CHOP.